Owen Richard T
Medical Information Department, Prous Science, Barcelona, Spain.
Drugs Today (Barc). 2006 Mar;42(3):185-92. doi: 10.1358/dot.2006.42.3.953589.
Patients with bipolar disorder tend to experience most of their illness in the depressed phase. Existing antidepressant therapies are effective in bipolar depression but carry a risk of treatment-emergent mania or increased phase cycling. Other therapies such as lithium may not be particularly effective, or may not currently be licensed for the acute phase, such as lamotrigine. A combination of the antipsychotic olanzapine and the serotonin reuptake inhibitor fluoxetine has been investigated in both bipolar depression and other affective disorders such as psychotic depression and treatment-refractory depression. The combination's possible mode of action, pharmacokinetics, drug interactions, clinical efficacy and safety and tolerability have been reviewed.
双相情感障碍患者在疾病的大部分时间里往往处于抑郁阶段。现有的抗抑郁疗法对双相抑郁有效，但存在治疗引发躁狂或增加发作循环的风险。其他疗法，如锂盐，可能效果不佳，或者目前未被批准用于急性期，如拉莫三嗪。抗精神病药物奥氮平与5-羟色胺再摄取抑制剂氟西汀的联合用药已在双相抑郁以及其他情感障碍（如精神病性抑郁和难治性抑郁）中进行了研究。对该联合用药可能的作用方式、药代动力学、药物相互作用、临床疗效、安全性及耐受性进行了综述。
